Prostate Cancer

A precursor of PSA detects more aggressive disease

Published in Cancer Weekly, July 29th, 2003

An inactive precursor form of PSA, prostate specific antigen, may prove better than the current standard of testing at detecting prostate cancer and identifying more aggressive forms of the disease, according to a study presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR).

PSA, an enzyme normally secreted by the prostate, is a well-known marker used to detect the presence of prostate cancer. As prostate cancer develops, a greater amount of PSA is released into the bloodstream. Current PSA tests measure "free" and "bound" PSA, yet often fail to distinguish between slow-growing cancers, which may take years to become...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry